EGFR and HER2 protein expression in AAH and adenocarcinoma of the lung
| Parameter | Adenocarcinoma | p Value | Total (n = 86) | |||
|---|---|---|---|---|---|---|
| AAH (n = 14) | BAC (n = 31) | Early MX (n = 22) | Overt MX (n = 33) | |||
| The Kruskal Wallis test was used to assess the p values among BAC, early MX, and overt MX. | ||||||
| AAH, atypical adenomatous hyperplasia; BAC, bronchioloalveolar carcinoma; EGFR, epidermal growth factor receptor; MX, adenocarcinoma with mixed subtypes. | ||||||
| EGFR | 0 | 1 (3.2%) | 8 (36.4%) | 15 (45.6%) | <0.0001 | 24 (27.9%) |
| HER2 | 0 | 1 (3.2%) | 6 (27.3%) | 11 (33.3%) | 0.0034 | 18 (20.9%) |
| Synchronous expression pattern | – | 1 (10%) | 3 (30%) | 6 (60%) | <0.0001 | 10 (11.6%) |